Cancer Prevention Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Tucson Arizona United States (2008)
Status: Acquired by Panbela Therapeutics (2022)

Organization Overview

First Clinical Trial
2010
NCT01059071
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cancer Prevention Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

eflornithine (ornidyl) (7 trials)

sulindac (clinoril) (4 trials)

Drugs in Phase 2 Trials (1)

dl-2-(difluoromethyl) ornithine (1 trial)

Drugs in Phase 1 Trials (1)

etoposide (vepesid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenoma (Phase 3)

Adenomatous Polyposis Coli (Phase 3)

Carcinogenesis (Phase 2)

Colorectal Neoplasms (Phase 3)

Metaplasia (Phase 2)

Nasopharyngeal Neoplasms (Phase 3)

Neuroblastoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4